Creative Medical Technology Holdings, Inc.
CELZNASDAQHealthcare● Active
$2.17
+$0.11(+5.31%)
Market Cap$5598479
P/E Ratio—
52W High$6.25
52W Low$1.504
Creative Medical Technology Holdings, Inc. (CELZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CELZ · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.38
Est. -$0.39 · +2.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CELZ reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.39 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.39 | -$0.38 | +2.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 20, 2026 | -$0.37 | -$0.80 | -116.2% | $0.00B | $0.00B | +0.0% |
| — Q4 FY2025 | Nov 7, 2025 | -$0.48 | -$0.48 | +0.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.63 | -$0.48 | +23.8% | — | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.52 | -$0.83 | -59.6% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 14, 2025 | -$0.63 | -$1.12 | -77.8% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.85 | -$0.75 | +11.8% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.38
EPS Est.
-$0.39
EPS Surpr.
+2.6%
Revenue
—
Q1 FY2026
Mar 20, 2026Miss
EPS Actual
-$0.80
EPS Est.
-$0.37
EPS Surpr.
-116.2%
Revenue
$0.00B
Q4 FY2025
Nov 7, 2025
EPS Actual
-$0.48
EPS Est.
-$0.48
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.48
EPS Est.
-$0.63
EPS Surpr.
+23.8%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.83
EPS Est.
-$0.52
EPS Surpr.
-59.6%
Revenue
$0.00B
Q1 FY2025
Mar 14, 2025Miss
EPS Actual
-$1.12
EPS Est.
-$0.63
EPS Surpr.
-77.8%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$0.75
EPS Est.
-$0.85
EPS Surpr.
+11.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q3 FY2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q2 FY2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q1 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2025 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q3 FY2025 | $-0.48 | $-0.48 | $-0.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +2.6% | $2.29 | $2.31 | +0.87% |
| ▼ Q1 FY2026 | Mar 20, 2026 | -116.2% | $1.88 | $1.84 | -2.13% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +0.0% | $2.97 | $3.02 | +1.68% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +23.8% | $3.73 | $3.33 | -10.72% |
| ▼ Q2 FY2025 | May 9, 2025 | -59.6% | $2.09 | $2.14 | +2.39% |
| ▼ Q1 FY2025 | Mar 14, 2025 | -77.8% | $3.00 | $3.27 | +9.00% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +11.8% | $3.16 | $2.81 | -11.08% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -32.1% | $3.02 | $2.92 | -3.31% |
Q2 FY2026+0.87%
Report Date
May 8, 2026
EPS Beat/Miss
+2.6%
Price Before
$2.29
Price After
$2.31
Q1 FY2026-2.13%
Report Date
Mar 20, 2026
EPS Beat/Miss
-116.2%
Price Before
$1.88
Price After
$1.84
Q4 FY2025+1.68%
Report Date
Nov 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.97
Price After
$3.02
Q3 FY2025-10.72%
Report Date
Aug 8, 2025
EPS Beat/Miss
+23.8%
Price Before
$3.73
Price After
$3.33
Q2 FY2025+2.39%
Report Date
May 9, 2025
EPS Beat/Miss
-59.6%
Price Before
$2.09
Price After
$2.14
Q1 FY2025+9.00%
Report Date
Mar 14, 2025
EPS Beat/Miss
-77.8%
Price Before
$3.00
Price After
$3.27
Q4 FY2024-11.08%
Report Date
Nov 8, 2024
EPS Beat/Miss
+11.8%
Price Before
$3.16
Price After
$2.81
Q3 FY2024-3.31%
Report Date
Aug 9, 2024
EPS Beat/Miss
-32.1%
Price Before
$3.02
Price After
$2.92
Avg Beat Reaction-4.81%
Avg Miss Reaction+1.49%
Beat Rate4 / 8 quarters
Largest Move-11.08% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CELZ ends December
Creative Medical Technology Holdings, Inc. (CELZ) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.38 — beating the analyst consensus of $-0.39 by +2.6%. The next CELZ earnings date is expected around September 1, 2026.
Each quarter, investors track CELZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CELZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CELZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CELZ earnings · 5 questionsCreative Medical Technology Holdings, Inc.'s next earnings report is expected around September 1, 2026. CELZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CELZ historically reports after market close (AMC).
CELZ earnings datewhen is CELZ earningsCELZ next earnings datewhen does CELZ report earningsCELZ earnings calendar
▸ Source: FMP · Creative Medical Technology Holdings, Inc. SEC filings · US GAAP · Creative Medical Technology Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026